


## CLAIMS

1. A prostaglandin derivative represented by  
Formula (I):



wherein X is a halogen atom in the  $\alpha$ - or  $\beta$ -substitution, Y is an ethylene group, a vinylene group or an ethynylene group,  $R^1$  is a  $C_{3-10}$  cycloalkyl group, a  $C_{3-10}$  cycloalkyl group substituted with a  $C_{1-4}$  straight or branched chain alkyl group or a  $C_{4-13}$  cycloalkylalkyl group,  $R^2$  is a hydrogen atom or a  $CO_2R^3$  group ( $R^3$  is a hydrogen atom, a  $C_{1-4}$  straight or branched chain alkyl group or a  $C_{2-4}$  straight or branched chain alkenyl group), n is an integer of 1 to 4 and p is 0, 1 or 2,  
a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. The prostaglandin derivative represented by  
Formula (I) according to claim 1, wherein  $R^1$  is a  $C_{3-10}$

cycloalkyl group or a C<sub>4-13</sub> cycloalkylalkyl group, a pharmaceutically acceptable salt thereof or a hydrate thereof.

5                   3. The prostaglandin derivative represented by Formula (I) according to claim 1 or 2, wherein X is a chlorine atom or a bromine atom in the  $\alpha$ - or  $\beta$ -substitution.

10                   4. The prostaglandin derivative represented by Formula (I) according to any of claims 1-3, wherein Y is an ethynylene group, a pharmaceutically acceptable salt thereof or a hydrate thereof.

15                   5. The prostaglandin derivative represented by Formula (I) according to any of claims 1-4, wherein R<sup>2</sup> is a CO<sub>2</sub>R<sup>3</sup> group, a pharmaceutically acceptable salt thereof or a hydrate thereof.

20                   6. The prostaglandin derivative represented by Formula (I) according to any of claims 1-5, wherein p=0, a pharmaceutically acceptable salt thereof or a hydrate thereof.

25                   7. The prostaglandin derivative represented by Formula (I) according to any of claims 1-6, wherein n=1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.

8. A pharmaceutical composition comprising the  
prostaglandin derivative according to any of claims 1-7, a  
pharmaceutically acceptable salt thereof or a hydrate  
thereof.

5